The 2012 hormone therapy position statement of: The North American Menopause Society.
about
Decision aids for the management of menopausal symptomsExercise for vasomotor menopausal symptomsAcupuncture for menopausal hot flushesBioidentical hormones for women with hot flushesBioidentical hormones for women with vasomotor symptomsAssociation of Mid-Life Changes in Body Size, Body Composition and Obesity Status with the Menopausal TransitionSex and Gender Differences in Central Nervous System-Related DisordersPatient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifeneThe Recent Review of the Genitourinary Syndrome of MenopauseWindow of opportunity: estrogen as a treatment for ischemic strokePrescribing menopausal hormone therapy: an evidence-based approachChallenging and complex decisions in the management of the BRCA mutation carrierCompounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy surveyManagement of Menopausal Symptoms.Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.Critical appraisal of paroxetine for the treatment of vasomotor symptomsModeling menopause: The utility of rodents in translational behavioral endocrinology researchLife-course origins of the ages at menarche and menopauseTrajectories and phenotypes with estrogen exposures across the lifespan: What does Goldilocks have to do with it?Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women.Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial.Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceBreast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexesTissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data.An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease.A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapyUse acupuncture to relieve perimenopausal syndrome: study protocol of a randomized controlled trial.Interventions to address sexual problems in people with cancerSex differences in cognitive impairment and Alzheimer's disease.Caring for the breast cancer survivor's health and well-being.Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary studyEstrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational StudyMenopause effects on verbal memory: findings from a longitudinal community cohort.Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.Treatment of postmenopausal women with topical progesterone creams and gels: are they effective?
P2860
Q24187423-28266F5C-E257-4F11-AE0C-606279992822Q24187786-0D3D89E8-3681-4D6F-AA4F-B9E33C495E27Q24200985-29705B0D-7B74-4E9F-8730-C2DAE2985493Q24201312-EDB17F78-F1AA-4E71-B236-9E8FB658CC8AQ26470545-8ACE38AD-41FD-4187-A8BC-FEA0FE6A0FB0Q26740255-802BCA54-7A16-472D-AABA-045F001AF42CQ26744569-ED2ED7DC-3AAC-4730-B0B3-ED500174D75DQ26751149-A4285957-61B0-47C5-B463-9E2EC2DF9444Q26781733-30F37826-9E61-47EC-98AB-3F96B70D80EDQ26828794-AF235D66-7324-4B96-BD73-E2BCF3FA3E1FQ27022920-556F63D6-7A76-4764-B66E-E22CB2AE2056Q27026559-0E497D49-F71B-4063-8BD2-9B89B7EF0402Q27317641-AFC9264D-20F9-4BFA-8C71-3B911B969988Q27318357-C2DCE4E0-D655-42E5-9F0E-CD79C8927470Q28081931-5302A630-3527-4D89-8F24-79A5F2B7BCAAQ28084597-F1D0C400-285B-4CD7-85C8-435FFBC27A81Q28392016-6ECBCF31-28FC-4AF2-B64F-D5E0A267F521Q28395419-69BEA236-B6A1-4651-A059-761C69321630Q28600847-A86F2455-69FD-454D-93CF-199F7EDC7A23Q30370912-E41EB43A-F096-44DE-86F8-67CC5819AF74Q30374316-F2D8795B-3E4D-4095-BDA2-A9BD28221885Q30380010-05DB0744-2178-4F3B-9254-B4648B53C349Q30409045-B82A9846-9D21-4DE1-B3BA-67FC19DB2A0BQ30456770-A6C20F42-82C8-474D-900C-2184A2806E70Q30659580-AD34CACC-B50D-4E52-86AE-50C7EB0F0D5CQ30696956-9FB5A770-32FD-42F0-A810-8538503F5F4FQ33605919-B798CFD1-0516-4D77-AB88-6AC6D1D9F419Q33747431-44BEF219-5D32-46C1-826C-33D736603946Q33840155-43CE0231-46F8-4E38-9EAC-9044D81A007BQ33864547-F2571586-F758-4D9F-905F-FA047C37BE25Q34031251-4726632F-36D5-4745-A485-D95A309561E4Q34147730-C3111630-3D6B-4636-BD1E-ADA1BDAB4ACBQ34243328-A0CF7C58-F7B2-4DCC-A0EB-2E69254CFF0DQ34266113-1B688010-5920-400A-9DBF-6827A29E4BCCQ34319242-C8CC20BD-B862-4A99-A9FF-0A435BB77F34Q34330784-DF5814BB-5CB7-490A-88EE-E7D155E122E9Q34336219-8CFC7CC2-5FB1-489D-ADE3-B5CE50E12FAAQ34356193-2B8FC524-0325-410B-974B-A015661E3137Q34362281-5018A29C-A286-4DDB-B854-86C1FA102538Q34437268-8ADCB469-31FB-416C-99B2-E10B31225B4F
P2860
The 2012 hormone therapy position statement of: The North American Menopause Society.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The 2012 hormone therapy position statement of: The North American Menopause Society.
@ast
The 2012 hormone therapy position statement of: The North American Menopause Society.
@en
The 2012 hormone therapy position statement of: The North American Menopause Society.
@nl
type
label
The 2012 hormone therapy position statement of: The North American Menopause Society.
@ast
The 2012 hormone therapy position statement of: The North American Menopause Society.
@en
The 2012 hormone therapy position statement of: The North American Menopause Society.
@nl
prefLabel
The 2012 hormone therapy position statement of: The North American Menopause Society.
@ast
The 2012 hormone therapy position statement of: The North American Menopause Society.
@en
The 2012 hormone therapy position statement of: The North American Menopause Society.
@nl
P2860
P1433
P1476
The 2012 hormone therapy position statement of: The North American Menopause Society.
@en
P2093
North American Menopause Society
P2860
P304
P356
10.1097/GME.0B013E31824B970A
P407
P577
2012-03-01T00:00:00Z